Anvisa Broad Indication of Meningitis Vaccine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
Brasilia, Sep 9 (Latin Press) Brazil's National Health Surveillance Agency (Anvisa) today extended the indication of a meningitis vaccine, which can be applied to children from the age of six weeks. The post Expanded in Brazil use of meningitis vaccine first appeared on Noticias Prensa Latina.
The National Agency for Health Surveillance (Anvisa) approved the extension of the MenQuadfi vaccine against meningitis for children from 6 weeks of age. The decision was taken last Tuesday (08/09) and allows the immunizer to be used in the prevention of invasive meningococcal disease caused by serogroups A, C, W and Y of the Neisseria meningitidis bacterium.MenQuadfi is a conjugated meningococcal vaccine applied intramuscularly. The change in t…
The National Agency for Health Surveillance (Anvisa) approved the extension of the MenQuadfi vaccine indication for children from 6 weeks of age. The decision allows the immunizer to be used in both adults and children for the prevention of invasive meningococcal disease caused by serogroups A, C, W and Y of the bacteria Neisseria meningitidis. A [...] The post Anvisa broad indication of meningitis vaccine appeared first in North Tribune.
Correio do Povo
Target audience begins to include babies from six weeks of life
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
